In the study, patients with relapsed or refractory multiple myeloma who received romidepsin in combination with Velcade and dexamethasone had an overall response rate of 85% (17/20). Approximately
This first study was a double-blind, placebo-controlled, randomized, single, oral, ascending dose trial performed in 71 healthy male and female volunteers. The primary objective of the Phase I
According to the company, this new molecular diagnostic tool marks a major advancement in which medical treatments can be personalized to patients diagnosed with this deforming disease. The
NeuVax contains the E75 peptide which is one of the rare T-cell peptides that has been documented to elevate or boost pre-existing anti-cancer immunity in cancer patients. This
Mr Frederick brings to NovaRay 20 years of financial leadership in strategic planning, financial reporting, mergers, acquisitions and international finance. Prior to joining NovaRay, Mr Frederick was senior
According to the company, the test has a reported sensitivity of 97%, and a specificity of 91% in identifying squamous cell lung cancer. Classification accuracy was measured in
The project between Scynexis and Drugs for Neglected Diseases initiative (DNDi) was initiated in 2006 and will now run through March 2012. The collaboration includes partners at Pace
The financing includes funding from several angel networks including Bellingham Angels, Alliance of Angels, Keiretsu, Tacoma Angel Network and Zino Society. Robert Brown, CEO of Healionics, said: “This
ProStrakan now plans to launch Abstral in Germany and the UK in the first few weeks of 2009, with further launches across Europe during the year. Abstral (formerly
Infinity’s heat shock protein 90 (Hsp90) program comprises IPI-504 (retaspimycin hydrochloride for injection) and oral IPI-493. IPI-504 is in several clinical trials, including an international Phase III registration
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.